| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
With Targeted Drugs, Chronic Myelogenous Leukemia Therapy May Follow HIV's Model
| The first 150 words of the full text of this article appear below. |
The targeted therapy imatinib has been a major success for many patients with chronic myelogenous leukemia (CML). Recently the U.S. Food and Drug Administration (FDA) approved a second targeted agent, dasatinib, for CML patients who don't respond to imatinib.
That makes CML the first cancer to have two targeted agents that are effective enough to be used alone. And more agents are in the works. With such riches, leukemia specialists are trying to figure out how best to use the agents: alone, in sequence, or together.
As more and better targeted drugs are developed for other cancers, the researchers' efforts in CML may serve as a model for how to move forward in similar situations in the future. Some experts suggest that the model already exists.
"The reality is that we already have that paradigm with HIV [human immunodeficiency virus], and we are just reinventing it with cancer," said Brian
Dasatinib Data
Which Drug for First-line?
Combination Therapy?
The T315I Problem
Affordability Question
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate Blood, August 1, 2008; 112(3): 793 - 804. [Abstract] [Full Text] [PDF]
|
|